Loading...
XNAS
CNTA
Market cap2.10bUSD
Jul 18, Last price  
15.69USD
1D
-1.69%
1Q
27.61%
IPO
-33.46%
Name

Centessa Pharmaceuticals PLC

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
10.06%
Rev. gr., 5y
%
Revenues
0k
-100.00%
00006,853,0000
Net income
-236m
L+56.04%
-5,284,000-11,041,000-381,854,498-216,207,000-151,085,000-235,757,000
CFO
-142m
L-11.40%
-5,825,000-10,630,000-136,141,777-200,546,000-160,342,000-142,055,000

Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
IPO date
May 28, 2021
Employees
64
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
6,853
 
Cost of revenue
201,055
178,136
210,414
Unusual Expense (Income)
NOPBT
(201,055)
(171,283)
(210,414)
NOPBT Margin
Operating Taxes
2,844
(25,056)
(747)
Tax Rate
NOPAT
(203,899)
(146,227)
(209,667)
Net income
(235,757)
56.04%
(151,085)
-30.12%
(216,207)
-43.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
359,605
20,807
718
BB yield
-18.75%
-2.72%
-0.25%
Debt
Debt current
Long-term debt
16,572
93,476
69,800
Deferred revenue
Other long-term liabilities
108,969
29
38,338
Net debt
(465,605)
(163,073)
(323,844)
Cash flow
Cash from operating activities
(142,055)
(160,342)
(200,546)
CAPEX
(34)
(169)
(1,137)
Cash from investing activities
31,267
(127,004)
(931)
Cash from financing activities
364,752
21,117
457
FCF
(183,433)
(177,282)
(210,673)
Balance
Cash
482,177
256,549
393,644
Long term investments
Excess cash
482,177
256,206
393,644
Stockholders' equity
(984,130)
(751,179)
(603,092)
Invested Capital
1,502,930
1,072,040
1,007,479
ROIC
ROCE
EV
Common stock shares outstanding
114,473
96,178
93,401
Price
16.75
110.43%
7.96
156.77%
3.10
-72.47%
Market cap
1,917,430
150.46%
765,574
164.41%
289,542
-71.42%
EV
1,451,825
602,501
(34,302)
EBITDA
(200,113)
(170,473)
(210,283)
EV/EBITDA
0.16
Interest
10,090
9,906
7,033
Interest/NOPBT